XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
 
Disaggregated Revenue
 
The following table reflects total revenue, net for the three months ended March 31, 2024 and 2023 (in thousands): 
Three Months Ended March 31,
20242023
Product sales, net:
ROLVEDON$14,478 $— 
INDOCIN products8,682 30,346 
Sympazan2,617 2,502 
Otrexup2,882 2,822 
SPRIX1,437 1,889 
CAMBIA1,256 2,264 
Other products510 1,946 
Total product sales, net31,862 41,769 
Royalties and milestone revenue586 697 
Total revenues$32,448 $42,466 
Product Sales, net

As a result of the Spectrum Merger, the Company began recognizing ROLVEDON sales in August 2023.

Other net product sales for the three months ended March 31, 2023 include product sales for OXAYDO and Zipsor. The Company ceased OXAYDO product sales beginning in September 2023.
Royalties and Milestone Revenue

In November 2010, the Company entered into a license agreement granting Miravo the rights to commercially market CAMBIA in Canada. Miravo independently contracts with manufacturers to produce a specific CAMBIA formulation in Canada. The Company recognized royalties revenue related to the CAMBIA licensing agreement of $0.6 million and $0.5 million for the three months ended March 31, 2024 and 2023, respectively.

The Company recognized no milestone revenue associated with the completion of certain service milestones for the three months ended March 31, 2024, and $0.2 million for the three months ended March 31, 2023.